Welcome to our dedicated page for Electrocore SEC filings (Ticker: ECOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to electroCore, Inc. (Nasdaq: ECOR) SEC filings, offering a detailed view of how the company reports its activities as a commercial-stage bioelectronic medicine and wellness business. electroCore focuses on non-invasive neuromodulation and bioelectronic technologies, including its gammaCore nVNS and Quell neurostimulator prescription products and its Truvaga and TAC-STIM wellness and performance devices.
Through forms such as the annual report on Form 10-K and quarterly reports on Form 10-Q, investors can review discussions of electroCore’s business, risk factors, financial condition, and operating results. Current reports on Form 8-K, several of which are referenced in the input data, disclose material events including quarterly financial results, private placements of common stock to satisfy specific obligations, and changes in the composition and leadership of the board of directors.
Other filings may cover topics such as stockholder votes on charter amendments, advisory votes on executive compensation, and the appointment of new independent directors or committee members. Together, these documents outline electroCore’s governance practices, capital structure developments, and key financial metrics over time.
On Stock Titan, these SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain the contents of lengthy reports, highlight important sections of 10-K and 10-Q filings, and clarify the implications of Form 8-K disclosures. Users can also review insider-related filings such as Form 4, where available, to see reported transactions by directors and officers. This combination of primary documents and AI-generated insights is intended to make electroCore’s regulatory record more accessible to a wide range of readers.
electroCore, Inc. filed a resale prospectus registering up to 762,508 shares of common stock for offer and sale by selling stockholders. The registration covers 295,420 Conversion Shares issuable upon conversion of up to $2,500,000 of loan principal at $8.4625 per share, 106,351 Private Placement Shares issued to Avenue in connection with the loan, and 360,737 Private Shares issued in October 2025 private placements. The company is not selling any securities in this prospectus and will not receive proceeds from any resale.
The shares stem from an August 4, 2025 Loan and Security Agreement providing up to $12.0 million in term loans (including a funded $7.5 million tranche) maturing on August 1, 2029, with a minimum interest rate of 12.50% and a conversion right for Avenue tied to the Conversion Shares. Including representative holders, this registration lists, among others, Avenue Venture Opportunities Fund II, L.P. 401,771 and Dentons US LLP 272,108. Shares outstanding were 7,995,903 as of October 2, 2025.
electroCore (ECOR) filed a resale registration covering up to 762,508 shares of common stock. The prospectus permits selling stockholders to resell shares from time to time using various methods at fixed, market, or negotiated prices. The company is not selling any securities in this offering and will not receive proceeds from stockholder sales.
The registered shares include 295,420 Conversion Shares issuable upon conversion of up to $2,500,000 of loan principal at a conversion price of $8.4625 per share, 106,351 Private Placement Shares issued to Avenue in connection with a loan agreement, and 360,737 Private Shares issued in October 2025 private placements at $5.145 per share. The Private Shares were issued in exchange for approximately $1.856 million of legal services. electroCore will bear registration expenses; selling holders will bear any selling commissions.
Common stock trades on Nasdaq as ECOR; the closing price was $5.12 per share on October 2, 2025. Shares outstanding were 7,995,903 as of October 2, 2025.
electroCore, Inc. entered into private securities purchase agreements with institutional and accredited investors, issuing 360,737 shares of common stock at $5.145 per share.
The shares were used to satisfy outstanding legal fee obligations, so the company received no cash. The unregistered shares were issued in reliance on Section 4(a)(2) and Regulation D, and electroCore agreed to file a registration statement to cover their resale within 90 days after the October 2, 2025 closing.
electroCore, Inc. filed a Form D as a new notice reporting a private securities offering under Rule 506(b). The issuer is a Delaware corporation headquartered in Rockaway, New Jersey. The filing indicates an indefinite offering with $0 sold to date and 0 investors so far. The filing discloses an inducement award: on September 10, 2025 Andy Brown was granted 10,000 restricted stock units (RSUs) outside existing plans under Nasdaq Listing Rule 5635(c)(4). The minimum investment is listed as $0, there are no sales commissions or finders fees reported, and the Form D was signed by CFO Joshua S. Lev on September 16, 2025. The company classified its industry as Other Health Care and identified issuer size as over $100,000,000.
Hilve Holdings Limited and Mikhail Stiskin disclosed beneficial ownership of 432,000 shares of electroCore, Inc. common stock, representing 5.7% of the outstanding shares based on 7,583,445 shares outstanding as of August 5, 2025. Hilve Holdings, a Cyprus company, holds the shares directly and has sole voting and dispositive power over them. Mr. Stiskin, an Israeli citizen and sole shareholder of Hilve Holdings, may be deemed the beneficial owner with identical sole voting and dispositive power. The filing states the stake was not acquired to change or influence control of the issuer.
electroCore, Inc. director Patricia Wilber received an annual award of 19,011 restricted stock units (RSUs) on 09/02/2025 that vest in 12 equal monthly installments from the grant date, but will vest in full earlier if the company holds its next annual meeting or upon a change of control, provided she remains in continuous service.
Following this grant, Ms. Wilber beneficially owns 72,325 shares, which includes 16,583 shares that vested from prior RSU grants and were previously reported. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/04/2025.
Julie Ann Goldstein, a director of electroCore, Inc. (ECOR), reported an award of 19,011 Annual Deferred Stock Units on 09/02/2025. The units were issued at a $0.00 price and vest in 12 equal monthly installments from the grant date; they vest in full earlier if the reporting person remains in service until the close of business one business day prior to the issuer's next annual stockholder meeting or immediately prior to a change of control. Following the grant, the filing reports 101,387 shares beneficially owned, which includes 10,000 previously vested shares and 1,665 shares held in NeuroSpine Ventures for which the reporting person disclaims beneficial ownership except for pecuniary interest. The Form 4 was signed by attorney-in-fact John L. Cleary, II on 09/04/2025.
electroCore, Inc. director Thomas J. Errico reported an award of 26,615 annual deferred stock units (DSUs) granted on 09/02/2025. The DSUs vest in 12 equal monthly installments from the grant date but will vest in full earlier if the holder remains in service until the next annual meeting or upon a change of control. Following the award, Errico beneficially owns 308,016 shares, composed of 217,051 directly owned shares, 1,296 shares held in a family trust, 11,000 held in another trust, and 52,054 shares that vested from prior DSUs. The DSUs carry no purchase price.
electroCore, Inc. director John P. Gandolfo was granted 19,011 Annual Deferred Stock Units on 09/02/2025 that vest in 12 equal monthly installments from the grant date, but accelerate to full vesting either one business day prior to the issuer's next annual stockholder meeting or immediately prior to a change of control, provided the reporting person remains in continuous service. After the grant, Mr. Gandolfo beneficially owns 88,098 shares, which includes 65,021 shares that had previously vested from earlier deferred unit grants.
electroCore, Inc. reported several corporate governance updates and voting results from its recent annual meeting. The Board appointed Elena Bonfiglioli, a senior healthcare and life sciences executive at Microsoft, as a new Class II director and expanded the Board from seven to eight members. She will receive the company’s standard non-employee director pay and an inaugural equity award.
The Board also named Thomas J. Errico, M.D. as chairman, succeeding F. Peter Cuneo, who retired and did not stand for re-election, with no disagreements cited regarding company matters. Director James C. Theofilos joined the Audit Committee.
Stockholders considered four proposals. An amendment to declassify the Board failed because it did not reach the required two-thirds of outstanding shares, despite 94.62% of votes cast supporting it. Three Class I directors were elected for terms expiring at the 2028 annual meeting, the appointment of CBIZ CPAs P.C. as independent auditor for 2025 was ratified, and named executive officer compensation was approved in a non-binding advisory vote.